Chinese Academy of Sciences

Dow Global Technolgoies LLC

East China University of Science and Technology

Cisen Pharmaceutical Co., Ltd.

Jingya Li

Jia Tao Li

Hualiang Jiang

Jian Li

Hong Tao Liu

Xiaomin Luo

Mei Zhang

Zhifu Xie

Wei Zhang

Jian Wang

Jiang Wang

Kaixian Chen

Fajun Nan

Lei Shi

Yijian Lin

Hui Chen

Haiyang Yu

Lihong Hu

Mingbo Su

Xin Huang

Dan Li

Yunfeng Yang

Honglin Li

Zhenjiang Zhao

Yufang Xu

Hong Liu

Shengbin Zhou

Shijie Ren

Yi Zang

Shiliang Li

Yi Wei

Dandan Sun

Jia Li

Edward W Kraegen

Dakai Chen

Jiming Ye

Jie Lian

Runtao Zhang

Lina Zhang

Dongdong Guo

Jingtao Wang

Hankun Zhang

Yibing Wang

Hongling Xu

David E James

Zhe Cheng

Provided are meltblown nonwovens, and articles thereof. The meltblown nonwovens can be formed form a composition comprising an ethylene/alpha-olefin interpolymer and specific additive. The meltblown nonwovens according to embodiments disclosed herein exhibit a high volume resistivity and can be used in filtration applications.

Meltblown nonwovens having high volume resistivity and articles thereof

Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.

Pharmaceutical use of thiophene [3,2-d] pyrimidine-4-ketone compound

The invention describes a polymorph of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid maleate and a preparation method therefor. The polymorph is a crystal having high stability and low hygroscopicity, and the crystal form is selected from crystal form A, crystal form B and crystal form C. Furthermore, the crystal form has a strong in-vivo hypoglycemic activity and can be used for the preparation of a novel drug for the treatment or prevention of diabetes mellitus type H and/or complications of diabetes mellitus type H.

Polymorph of DPPIV inhibitor maleate and preparation method therefor

The invention relates to a salt form of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid and a preparation method for the salt form. Also disclosed is a pharmaceutical composition of the formula I compound salt form. The salt form of the invention provides powerful in vivo hypoglycemic activity and is expected to be a novel pharmaceutical active ingredient for treating or preventing diabetes mellitus type 2 and/or complications of diabetes mellitus type 2 

Salt form of DPPIV inhibitor and preparation method thereof

C, O-spiro aryl glycoside compounds are provided. Specifically provided are C, O-spiro aryl glycoside compounds represented by the formula (I), wherein the definitions of each variable group are described in the specification. Also provided are methods of preparing and using the C, O-spiro aryl glycoside compounds. The C, O-spiro aryl glycoside compounds can be used as SGLT2 inhibitors and for treating diseases, such as diabetes, atherosclerosis, and adiposity. 

C,O-spiro aryl glycoside compounds, preparation therefor and use thereof

The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown in formula I, a pharmaceutical composition containing the compound as shown in formula I and a use of the compound in the preparation of drugs for treating DPP-4 related diseases or inhibiting DPP-4. 

Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof

The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes. 

Fatty acid compound, preparation method therefor and use therefor

The present invention relates to crystal form A of a compound. The present invention also discloses a preparation method and a pharmaceutical composition of the crystal form A. The crystal form A has strong hypoglycemic activity in vivo and is expected to be a novel pharmaceutically active ingredient for treating or preventing type II diabetes and/or complications of type II diabetes.

Crystal form A of compound and preparation method thereof

Provided are a class of pyrazolone compounds and a use thereof. In particular, a compound represented by formula I is provided, wherein the definition of each variable group is as described in the description. The compounds of formula (I) have a direct AMPK-activating activity and can significantly promote the phosphorylation of AMPK and ACC of L6 myocytes and HepG2 cells in a dose-dependent manner. 

One class of pyrazolone compounds and use thereof

Disclosed are new thienyl [3,2-d] pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes. 

Thienyl [3,2-D] pyrimidin-4-one compounds, preparation method, pharmaceutical compositions and use thereof

PTP1B inhibitors with the following structure (formula I). Experiments indicate that these inhibitors can effectively inhibit the activity of protein tyrosine phosphatase 1B (PTP1B). They can be used as insulin sensitisers. They can be used to prevent, delay or treat diseases which are related to insulin antagonism mediated by PTP1B, especially diabetes type II and obesity. The invention also provides methods for preparing these inhibitors. 

Protein tyrosine phosphatase 1B inhibitor, preparation methods and uses thereof

Growing community of inventors

Shanghai, China

Jingya Li